Clinical trial · Observational
Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
NCT07594496CI-TRIAL-00111818enrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the prevalence of cannabis withdrawal and the clinical manifestations of cannabis withdrawal syndrome in patients hospitalized for BMT or CAR-T therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematopoietic and Lymphatic System Neoplasm | Hematopoietic and Lymphatic System Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Malignant Solid Neoplasm | Malignant Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional Study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Patients complete surveys and have their medical records reviewed on study.
- interventionNames
- Other: Non-Interventional Study
Primary outcomes (2)
- measure
- Prevalence of cannabis withdrawal
- timeFrame
- Up to 1 year
- description
- Descriptive statistics will be utilized to summarize cannabis withdrawal prevalence.
- measure
- Severity of withdrawal symptoms
- timeFrame
- Daily for first 4 days of hospitalization
- description
- Assessed by the Cannabis Withdrawal Scale (CWS), a self-report instrument used measures the intensity of 19 cannabis withdrawal symptoms over the last 24 hours. Each item is rated on a 10-point Likert scale where 0=not al all and 10=extremely. Items are rated twice, first for intensity of symptom and then for negative impact on daily activity. Withdrawal symptom scores range from 0 to 190, with higher scores reflecting greater intensity of withdrawal symptoms.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All adult patients admitted for BMT or CAR-T therapy Exclusion Criteria: * Individuals unable to provide informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.